Gordiienko IM, Gubar OS, Sulik R, Kunakh T, Zlatskiy I, Zlatska A. Empty nose syndrome pathogenesis and cell-based biotechnology products as a new option for treatment. World J Stem Cells 2021; 13(9): 1293-1306 [PMID: 34630863 DOI: 10.4252/wjsc.v13.i9.1293]
Corresponding Author of This Article
Igor Zlatskiy, PhD, Senior Researcher, State Institute of Genetic and Regenerative Medicine, National Academy of Medical Sciences of Ukraine, Vyshgorodskaja Street, 67, Kyiv 04114, Ukraine. zlatskiy@ukr.net
Research Domain of This Article
Cell Biology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Sep 26, 2021; 13(9): 1293-1306 Published online Sep 26, 2021. doi: 10.4252/wjsc.v13.i9.1293
Empty nose syndrome pathogenesis and cell-based biotechnology products as a new option for treatment
Inna M Gordiienko, Olga S Gubar, Roman Sulik, Taras Kunakh, Igor Zlatskiy, Alona Zlatska
Inna M Gordiienko, Roman Sulik, Taras Kunakh, Alona Zlatska, Biotechnology Laboratory, Medical Company “Good Cells”, Kyiv 03115, Ukraine
Inna M Gordiienko, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology NAS of Ukraine, Kyiv 03022, Ukraine
Olga S Gubar, Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv 03143, Ukraine
Igor Zlatskiy, Alona Zlatska, State Institute of Genetic and Regenerative Medicine, National Academy of Medical Sciences of Ukraine, Kyiv 04114, Ukraine
Author contributions: All authors contributed equally to this work.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Igor Zlatskiy, PhD, Senior Researcher, State Institute of Genetic and Regenerative Medicine, National Academy of Medical Sciences of Ukraine, Vyshgorodskaja Street, 67, Kyiv 04114, Ukraine. zlatskiy@ukr.net
Received: February 28, 2021 Peer-review started: February 28, 2021 First decision: April 19, 2021 Revised: April 29, 2021 Accepted: August 13, 2021 Article in press: August 13, 2021 Published online: September 26, 2021 Processing time: 201 Days and 22.2 Hours
Core Tip
Core Tip: Empty nose syndrome is a complex disease, which pathogenesis is associated not only with changes in the architecture of the nasal passages, but also with changes in the receptor status of the nasal mucosa and disorders of perception of external stimuli at the systemic level. Due to the lack of effective convencial protocols for the treatment of this disease, there is a need to find new approaches to restoring the normal structure of the architecture of the nasal passages and return the functionality of the nasal mucosa. In addition, the proposed methods should be minimally invasive, implemented by injection. The advancement of regenerative medicine and biotechnology contributes to the development of new cell-based products in combination with various materials, which in the future will be able to help develop protocols for treatment patients with empty nose syndrome.
